CS
VOR icon

Credit Suisse’s Vor Biopharma VOR Stock Holding History

Credit Suisse’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1
Closed – – 4320
2022
Q2 		$0 Buy
+1
New +$102 ﹤0.01% 4352

Other funds holding VOR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Credit Suisse's VOR Position: Q3 2022 in Review

Credit Suisse sold out of Vor Biopharma (VOR) in Q3 2022, closing a stake of 1 share.

Credit Suisse first reported a position in VOR in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 48 funds tracked by Wall St. Rank hold VOR as of Q3 2022.

  • Credit Suisse reported no remaining Vor Biopharma position as of Q3 2022 after selling out during the quarter.
  • Credit Suisse sold 1 Vor Biopharma share in Q3 2022.
  • Credit Suisse first reported a position in Vor Biopharma in Q2 2022 and held it in 1 quarter.
  • Credit Suisse's Vor Biopharma position peaked at $0 in Q2 2022.
  • 48 funds tracked by Wall St. Rank held Vor Biopharma as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.